YCYanfei Chen

Yanfei Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yanfei Chen has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Two different distal protections on cerebral microembolization of vulnerable plaque during carotid artery stenting (CASH-ES): study protocol for a randomized controlled trial

    by Lin Yan, Liqi Shu, Sun Xinyi, Nan Zhang, Yake Lu, Yiding Feng, Yabing Wang, Peng Gao, Yan Ma, Jian Chen, et al.

    Carotid artery stenting (CAS) is a widely used procedure for patients with high-risk carotid stenosis, particularly in the Chinese population. However, there are no randomized trials examining the comparative efficacy and safety of different embolic protection devices (EPDs) used during CAS. This study aims to evaluate the safety and effectiveness of two newer-generation EPDs, Spider FX™ and Emboshield NAV6™, using a comprehensive approach that includes intraoperative monitoring, postoperative imaging, and clinical outcomes. Given the specific focus on a Chinese population, caution should be applied when generalizing findings to other ethnic groups. This is a prospective, single-center, randomized, controlled, and blinded-endpoint trial designed to compare the performance of Spider FX™ and Emboshield NAV6™ in high-risk carotid stenosis patients undergoing CAS. A total of 172 patients will be enrolled, accounting for an estimated 20% dropout rate. The randomization will be performed in a 1:1 ratio between the two devices. The primary outcome is new ipsilateral ischemic lesions on diffusion-weighted imaging (DWI) within 7 days after CAS. Secondary outcomes include the number, size, and location of new cerebral ischemic lesions on DWI, and the count of microembolic signals (MES) detected by TCCD monitoring during the procedure. Safety assessments will include procedural complications, myocardial infarction, and mortality within 7 days. The results of this trial will provide crucial evidence on whether the Emboshield NAV6™ device offers superior distal embolic protection compared to the Spider FX™ in patients undergoing CAS. This could potentially guide clinicians in selecting the most effective EPD for high-risk carotid stenosis patients. ClinicalTrials.gov NCT04904250 (URL: http://www. gov) Registered on May 27, 2021.

  • Open Access

    Bow Hunter's Syndrome: Illustrative Teaching Case with Insights and Lessons

    by Tianyu Jin, Yanfei Chen, Zan Chen, Wanru Duan

    A 63-year-old woman with a history of left basal ganglia and paraventricular infarcts, type II diabetes, and hypertension presented with recurrent dizziness when turning her head to the right. These episodes, lasting for eight months, were often accompanied by nausea and vision disturbances but resolved spontaneously. Dynamic digital subtraction angiography (DSA) revealed significant blood flow slowdown in the left vertebral artery (VA) with a 90° right neck turn, showing narrowing in the V3 segment of the left VA. The patient was diagnosed with Bow Hunter's Syndrome (BHS) and underwent atlantoaxial fusion surgery. On day three post-surgery, she developed sudden weakness in the left upper limb, visual field hemianopia, impaired sensation, and slurred speech. Emergency CT and MRI revealed acute infarcts in the basal ganglia and periventricular area. Following antiplatelet therapy and volume expansion, her symptoms improved, and by day seven, her speech and left upper limb strength had partially recovered, though residual symptoms persisted at discharge. One year post-surgery, the dizziness had resolved, but residual symptoms from the infarction remained. Cervical fusion effectively treated the symptoms of BHS; however, surgery should be considered with caution in patients with thromboembolic risk factors.

  • Open Access

    A prospective multicenter, randomized controlled, non-inferiority trial of bovine pericardial versus polyurethane patching in carotid endarterectomy

    by Yanfei Chen, Yao Feng, Xiao Tang, Yabo Huang, Peng Zhou, Liyong Zhang, Jiheng Hao, Zhen Li, Zhaohui Hua, Daqiao Gao, et al.

    Carotid endarterectomy (CEA) is the first-line treatment for internal carotid artery stenosis that can lead to stroke. This study aimed to compare the incidence of early adverse clinical events and restenosis between patient groups receiving the newly developed bovine pericardial (BP) and polyurethane patches during CEA. We conducted a multicenter, randomized, non-inferiority trial at five tertiary centers in China. Participants were assigned to either the BP patch or polyurethane patch group. The primary outcome was freedom from restenosis at 1 year after surgery. Restenosis was defined as a narrowing of >50% in the target artery on duplex ultrasound or computed tomography angiography examination. The total number of participants was 120, including 60 each randomized to the BP patch and polyurethane patch groups. Demographics were similar in both groups. Death or significant disability was comparable between the two groups (3:1, p = 0.619) during the perioperative period. At the 12-month assessment (n = 112), three patients had severe restenosis: two in the BP patch group (n = 57) and one in the polyurethane patch group (n = 55). There was no significant statistical difference in restenosis, morbidity, or mortality between the two groups (p > 0.4), indicating that the BP patch was non-inferior to the polyurethane patch (p = 0.013 for the full analysis set; p = 0.016 for the per-protocol set). The two groups of patches had similar safety and effectiveness, and the BP patch was non-inferior to the mature polyurethane patch available on the market.

  • Open Access

    Impact of immediate postrecanalization cooling on outcome in acute ischemic stroke patients with a large ischemic core: prospective cohort study

    by Xuesong Bai, Xin Qu, Raul G. Nogueira, Wenhuo Chen, Hao Zhao, Wenbo Cao, Peng Gao, Bin Yang, Yabing Wang, Jian Chen, et al.

    Background: Patients with large acute ischemic strokes (AIS) often have a poor prognosis despite successful recanalization due to multiple factors including reperfusion injury. The authors aim to describe our preliminary experience of endovascular cooling in patients with a large AIS after recanalization. Methods: From January 2021 to July 2022, AIS patients presenting with large infarcts (defined as ASPECTS ≤5 on noncontrast CT or ischemic core ≥50 ml on CT perfusion) who achieved successful recanalization after endovascular treatment were analyzed in a prospective registry. Patients were divided into targeted temperature management (TTM) and non-TTM group. Patients in the TTM group received systemic cooling with a targeted core temperature of 33° for at least 48 h. The primary outcome is 90-day favorable outcome [modified Rankin Scale (mRS) 0–2]. The secondary outcomes are 90-day good outcome (mRS 0–3), mortality, intracranial hemorrhage and malignant cerebral edema within 7 days or at discharge. Results: Forty-four AIS patients were recruited (15 cases in the TTM group and 29 cases in the non-TTM group). The median Alberta Stroke Program Early CT Score (ASPECTS) was 3 (2–5). The median time for hypothermia duration was 84 (71.5–147.6) h. The TTM group had a numerically higher proportion of 90-day favorable outcomes than the non-TTM group (46.7 vs. 27.6%, P=0.210), and no significant difference were found regarding secondary outcomes (all P>0.05). The TTM group had a numerically higher rates of pneumonia (66.7 vs. 58.6%, P=0.604) and deep vein thrombosis (33.3 vs. 13.8%, P=0.138). Shivering occurred in 4/15 (26.7%) of the TTM patients and in none of the non-TTM patients (P=0.009). Conclusions: Postrecanalization cooling is feasible in patients with a large ischemic core. Future randomized clinical trials are warranted to validate its efficacy.


  • Open Access

    Impact of acute silent ischemic lesions on clinical outcomes of carotid revascularization

    by Jie Wang, Tao Wang, Bin Yang, Yanfei Chen, Peng Gao, Yabin Wang, Jian Chen, Fei Chen, Jichang Luo, Renjie Yang, et al.

    Background: Previous literature has established an association between acute silent ischemic lesions (ASILs) and elevated susceptibility to future adverse clinical outcomes. The present study endeavors to scrutinize the prognostic significance of preprocedural ASILs, as detected through diffusion-weighted imaging and apparent diffusion coefficient metrics, in relation to subsequent adverse events—namely, stroke, myocardial infarction, and all-cause death—following carotid revascularization in a cohort of patients with symptomatic carotid stenosis. Materials and methods: Subjects were extracted from a comprehensive retrospective dataset involving symptomatic carotid stenosis cases that underwent carotid revascularization at a tertiary healthcare institution in China, spanning January 2019 to March 2022. Of the 2663 initially screened patients (symptomatic carotid stenosis=1600; asymptomatic carotid stenosis=1063), a total of 1172 individuals with symptomatic carotid stenosis were retained for subsequent analysis. Stratification was implemented based on the presence or absence of ASILs. The primary endpoint constituted a composite measure of in-hospital stroke, myocardial infarction, or all-cause death. Both carotid endarterectomy (CEA) and carotid artery stenting (CAS) treatment modalities were individually subjected to propensity score-matched analyses. Results: Among the 584 subjects who underwent CEA, 91 ASIL-positive and 91 ASIL-negative (NASIL) cases were propensity score-matched. Notably, the ASIL cohort demonstrated a statistically significant augmentation in the risk of primary outcomes relative to the NASIL group [10.99 vs. 1.10%; absolute risk difference, 9.89% (95% CI: 3.12–16.66%); RR, 10.00 (95% CI: 1.31–76.52); P=0.01]. Similarly, within the 588 CAS-treated patients, 107 ASIL-positive and 107 NASIL cases were matched, revealing a correspondingly elevated risk of primary outcomes in the ASIL group [9.35 vs. 1.87%; absolute risk difference, 7.48% (95% CI: 1.39–13.56%); RR, 5.00 (95% CI: 1.12–22.28); P=0.02]. Conclusions: ASILs portend an elevated risk for grave adverse events postcarotid revascularization, irrespective of the specific revascularization technique employed—be it CEA or CAS. Thus, ASILs may serve as a potent biomarker for procedural risk stratification in the context of carotid revascularization.


  • Open Access

    Potential predictors for progression of moyamoya disease: A systematic review and meta-analysis

    by Jun Cao, Zixuan Xing, Ling Dai, Tao Wang, Yuhai Zhang, Yao Feng, Yanfei Chen

    Background: The progress of Moyamoya disease (MMD) is often accompanied by the occurrence of new ischemia or hemorrhagic events, which was difficult to predict. This systematic review and meta-analysis aimed to identify predictors for progression in MMD patients.Methods: We searched PubMed, Web of Science, Cochrane Library, and Embase databases up to December 10th, 2022 for randomized controlled trials, case-control studies, or cohort studies reporting predictors of disease progression in MMD patients. The results of each predictor were pooled by meta-analysis and further analyzed by subgroup analysis for predictors of unilateral to bilateral progression of MMD.Results: A total of 842 patients from 12 studies were included. The estimated pooled means indicated lower age (standard mean difference [SMD]: −0.29, 95% confidence interval [CI]: −0.55 to −0.03; P = 0.03), family history (odds ratio [OR] 3.97, 95% CI: 1.96 to 8.03; P < 0.001) and contralateral abnormality (OR 3.95, 95% CI: 1.10 to 14.20; P = 0.04) were associated with progression in MMD patients. Subgroup analyses indicated that the same three factors were associated with the progression of unilateral to bilateral MMD.Conclusions: This meta-analysis revealed that lower age, family history and contralateral abnormality were associated with progression in MMD patients. The same three factors are associated with the progression of unilateral to bilateral MMD. Further studies are needed to validate our results.